|Bid||0.0000 x 3100|
|Ask||0.0000 x 4000|
|Day's Range||0.4410 - 0.5700|
|52 Week Range||0.4410 - 0.5700|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 2, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BERKELEY HEIGHTS, N.J., Feb. 21, 2019 -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the full-year ended December 31, 2018. Financial.
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK , Dec. 28, 2018 /PRNewswire/ -- Bluebird Bio, Inc. (BLUE) Lifshitz & Miller announces investigation into possible securities laws violations in connection with a report on Seeking Alpha noting ...
NEW YORK, NY / ACCESSWIRE / December 21, 2018 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the EmpireState Building in New York City, is investigating the Board of Directors of Edge Therapeutics, Inc. ("EDGE" or the "Company") (NASDAQ: EDGE)for possible breaches of fiduciary duty related to the sale of the company to PDS Biotechnology Corporation. The investigation focuses on whether EDGE and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company's stockholders by 1) failing to conduct a fair process, 2) whether and by how much this proposed transaction undervalues the Company by and 3) failing to disclose all material financial information in connection with the upcoming shareholder meeting.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed merger of Edge Therapeutics, Inc.
NEW YORK, Nov. 30, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
LONDON, Nov. 30, 2018 -- In late November 2018, NetScientific (AIM: NSCI) announced that its portfolio company PDS Biotechnology and Edge Therapeutics (NASDAQ: EDGE) will.
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK , Nov. 29, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...
NEW ORLEANS , Nov. 29, 2018 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger ...
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Zafgen was one of the big decliners in the biotech arena after the FDA put a clinical hold on its Investigational New Drug Application. Shares of Edge Therapeutics were also in the red after announcing a definitive merger agreement with PDS Biotechnology Corporation. Zafgen, Inc. shares sank on Monday nearly 40.5% at the close.
Do you own shares of Edge Therapeutics, Inc. (NASDAQ GS: EDGE)? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Edge Therapeutics, Inc. (“Edge Therapeutics” or the “Company”) (NASDAQ GS: EDGE) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with PDS Biotechnology Corporation (“PDS”). Under the terms of the agreement, shareholders of Edge Therapeutics will own approximately 30% of the combined company.
NEW YORK, Nov. 26, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Edge Therapeutics, Inc. (“Edge.
A reverse merger deal is a transaction in which an active private company merges with a dormant public company in a bid to go public without having to go through the arduous route of a traditional initial public offering. Edge announced a comprehensive review of strategic alternatives in April in a bid to maximize shareholder value.
Edge Therapeutics, Inc. (EDGE) and PDS Biotechnology Corporation, a privately-held, clinical-stage cancer immunotherapy company, announced today that their respective boards of directors have approved a definitive merger agreement. The merger is expected to create a combined company with a growing pipeline of next generation cancer immunotherapies based on the proprietary, multi-functional Versamune® technology platform, and sufficient cash to fund operations into 2020.
On a per-share basis, the Berkeley Heights, New Jersey-based company said it had a loss of 14 cents. Losses, adjusted for restructuring costs, came to 11 cents per share. The company's shares closed at ...
BERKELEY HEIGHTS, N.J., Nov. 01, 2018 -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the quarter ended September 30, 2018. Third Quarter.